



PolyNovo Limited
ABN 96 083 866 862
2/320 Lorimer Street
Port Melbourne
VIC Australia 3207
P +61 (0) 3 8681 4050

15 July 2025

ASX Announcement

Webcast Recording: Special Briefing with Prof Toby Coates

For shareholders and other interested parties who were unable to attend the special briefing with Professor Toby Coates live, or would like the opportunity to view it again, the recording can be viewed at the link below.

<https://vimeo.com/1101410085/9319bf9f34>

Professor Toby Coates is the Director of Kidney and Pancreatic Islet Transplant Surgery at Royal Adelaide Hospital. He recently used PolyNovo's NovoSorb BTM to aid in the successful transplant of islet cells into a long-term Type 1 diabetic. This is a new market for NovoSorb and demonstrates the flexibility and platform nature of the product.

This announcement has been authorised by PolyNovo Company Secretary, Jan Gielen.

About PolyNovo®

PolyNovo is a disruptive medical technology company, headquartered in Melbourne, Australia. Its products simplify management of acute complex wounds, redefining healing with meaningfully differentiated patient outcomes across multiple wound etiologies. The Company has treated 70,000+ patients in 46 countries and is investing for growth via new products, indications, and markets. For more information see polynovo.com.

About NovoSorb®

NovoSorb BTM is a dermal scaffold for the regeneration of the dermis when lost through extensive surgery, trauma or burn. NovoSorb is a novel range of bio-resorbable polymers that can be produced in many formats including film, fibre, foam, and coatings. NovoSorb's unique properties provide excellent biocompatibility, control over physical properties, and a programmable bio-resorption profile.